Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone diacetate ointment for psoriasis — a multicentre, randomized, double-blinded study

Abstract

The clinical efficacy and safety of 0.5% augmented betamethasone dipropionate ointment (Diprolene) and 0.05% diflorasone diacetate ointment (Psorcon) were evaluated in a multicentre randomized double-blind trial. A total of 164 patients with psoriasis from four geographic regions of the US were treated in this 2-week clinical study. One half received Diprolene ointment and the other half, Psorcon. After 2 weeks, both ointments significantly improved psoriasis (p < 0.001), but Diprolene ointment held a slight, but significant, advantage over Psorcon ointment in clinical efficacy. There was a high patient preference for Diprolene ointment which led to fewer adverse reactions.